Answers are grounded in this paper and cite their sources.
Learning Objectives After completing this course, the reader will be able to: List the strengths and limitations of the recurrence score and discuss how the TAILORx trial is trying to further the utility of the recurrence score.Describe the need for robust prognostic factors for estrogen receptor–positive and node-negative breast cancer treated with tamoxifen.Discuss the basic statistical requirements in prognostic marker development. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
No takes yet. Share an insight, caveat, or question.
Soonmyung Paik (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: